Clearmind Medicine Schedules Shareholder Meeting
Ticker: CMND · Form: 6-K · Filed: Nov 28, 2025 · CIK: 1892500
Sentiment: neutral
Topics: shareholder-meeting, proxy-materials, corporate-governance
TL;DR
Clearmind Medicine set Dec 29th for shareholder meeting, Nov 20th was record date.
AI Summary
Clearmind Medicine Inc. filed a Form 6-K on November 28, 2025, providing proxy materials for its Annual and Special Meeting of Shareholders scheduled for December 29, 2025. The record date for determining eligible shareholders was set as November 20, 2025.
Why It Matters
This filing informs shareholders about an upcoming meeting where key corporate decisions will be made, impacting the company's future direction and governance.
Risk Assessment
Risk Level: low — This is a routine filing related to a shareholder meeting and does not contain significant financial or operational news.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- December 29, 2025 (date) — Annual and Special Meeting Date
- November 20, 2025 (date) — Record Date for Shareholders
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K filing provides proxy materials for Clearmind Medicine Inc.'s Annual and Special Meeting of Shareholders.
When is the Annual and Special Meeting of Shareholders scheduled to take place?
The meeting is scheduled to be held on Monday, December 29, 2025.
What was the record date for determining shareholders entitled to notice of the meeting?
The board of directors fixed November 20, 2025, as the Record Date.
What type of company is Clearmind Medicine Inc. according to its SIC code?
Clearmind Medicine Inc. is classified under Pharmaceutical Preparations [2834].
Does Clearmind Medicine Inc. file annual reports under Form 20-F or 40-F?
Clearmind Medicine Inc. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 324 words · 1 min read · ~1 pages · Grade level 11.1 · Accepted 2025-11-28 16:01:36
Filing Documents
- ea0267630-6k_clearmind.htm (6-K) — 12KB
- ea026763001ex99-1_clearmind.htm (EX-99.1) — 799KB
- ea026763001ex99-2_clearmind.htm (EX-99.2) — 8KB
- ea026763001ex99-3_clearmind.htm (EX-99.3) — 9KB
- ea026763001ex99-4_clearmind.htm (EX-99.4) — 2KB
- ex99-2_001.jpg (GRAPHIC) — 666KB
- ex99-2_002.jpg (GRAPHIC) — 608KB
- ex99-3_001.jpg (GRAPHIC) — 773KB
- ex99-3_002.jpg (GRAPHIC) — 613KB
- ex99-4_001.jpg (GRAPHIC) — 431KB
- 0001213900-25-116075.txt ( ) — 5087KB
Financial Statements Request Form
Financial Statements Request Form 2 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: November 28, 2025 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3